paxlovid
oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) Science Pfizer Worldwide Research
Molecules of the Month - November 2021
Molecules of the Month
- paxlovid
- GS-621763
- ASP2453
- SY-5609
- BIIB091
- "compound Ia"
- DS96432529
- "compound 27"
- tepotinib
- PF-06939999
- "compound 5"
- compound 59
- M5717
- compound 1